123 completed. 123 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 123 | Completed 123 |
| Phase 2 | 12 | Completed 12 |
Follow Colitis, Ulcerative: new trials by email Literature Review of Colitis, Ulcerative trials Research Report on Colitis, Ulcerative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis Mirikizumab IV, Mirikizumab SC - Ulcerative Colitis | Phase 3 | Completed | Eli Lilly and Company | 63 | 2023-11-22 | 2026-06-03 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis Mirikizumab - Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 3 | Completed | Eli Lilly and Company | 172 | 2023-05-17 | 2026-06-10 |
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 636 | 2023-01-25 | 2026-09-10 |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 639 | 2022-11-16 | 2026-09-10 |
| Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease Frondanol, Placebo - Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | Phase 2 / Phase 3 | Completed | Mohammed Bin Rashid University of Medicine and Health Sciences | 13 | 2022-02-19 | 2024-11-20 |
| A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) Vedolizumab - Colitis, Ulcerative | Phase 3 | Completed | Takeda | 121 | 2021-10-19 | 2026-04-30 |
| A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo - Colitis, Ulcerative | Phase 3 | Completed | Janssen Research & Development, LLC | 112 | 2021-03-17 | 2026-10-20 |
| Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN) Etrasimod, Placebo - Ulcerative Colitis | Phase 3 | Completed | Pfizer | 42 | 2020-12-25 | 2023-10-16 |
| Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention - Ulcerative Colitis | Phase 3 | Completed | University of Miami | 32 | 2020-09-18 | 2025-02-28 |
| Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 3 | Completed | Arena Pharmaceuticals | 354 | 2020-09-15 | 2022-12-21 |
| CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) CT-P13 SC (Infliximab), Placebo SC - Ulcerative Colitis | Phase 3 | Completed | Celltrion | 548 | 2020-09-01 | 2023-09-28 |
| ENhanced Recovery in CHildren Undergoing Surgery Perioperative surgical care - Inflammatory Bowel Disease, Crohn's Disease | Phase 3 | Completed | Northwestern University | 597 | 2020-07-01 | 2026-08-07 |
| Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan Probiotic Formula Capsule, Placebos - Ulcerative Colitis | Phase 2 / Phase 3 | Completed | University of Jordan | 30 | 2020-01-15 | 2024-09-19 |
| Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 3 | Completed | Arena Pharmaceuticals | 433 | 2019-06-13 | 2022-12-20 |
| To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis Ozanimod, Placebo - Colitis, Ulcerative | Phase 3 | Completed | Celgene | 198 | 2019-06-03 | 2025-10-15 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis Placebo, Upadacitinib - Ulcerative Colitis (UC) | Phase 3 | Completed | AbbVie | 522 | 2018-12-06 | 2022-03-02 |
| A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Mirikizumab SC, Mirikizumab IV, Placebo SC - Ulcerative Colitis | Phase 3 | Completed | Eli Lilly and Company | 1328 | 2018-10-19 | 2026-05-13 |
| An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Mirikizumab, Placebo - Ulcerative Colitis | Phase 3 | Completed | Eli Lilly and Company | 1281 | 2018-06-18 | 2025-05-31 |
| A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis AJM300, Placebo - Colitis, Ulcerative | Phase 3 | Completed | EA Pharma Co., Ltd. | 198 | 2018-06-06 | 2023-07-21 |
Showing 20 of 123. Sign in to see all of them.
Inflammatory Bowel Diseases (22) · Colitis (10) · Crohn Disease (10) · Ulcer (5) · Gastrointestinal Diseases (4) · Colonic Diseases (3) · Digestive System Diseases (3) · Gastroenteritis (3) · Intestinal Diseases (3) · Anemia (2) · Anemia, Iron-Deficiency (2) · Iron Deficiencies (2) · Pathologic Processes (2) · Patient Acceptance of Health Care (2)
Colonic Diseases (120) · Digestive System Diseases (120) · Gastroenteritis (120) · Intestinal Diseases (120) · Gastrointestinal Diseases (119) · Colitis (113) · Inflammatory Bowel Diseases (101) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (7) · Disease Attributes (4) · Behavior (3) · Health Behavior (3) · Hemic and Lymphatic Diseases (3) · Treatment Adherence and Compliance (3) · Anemia, Hypochromic (2)
Mesalamine (27) · Adalimumab (12) · Budesonide (6) · Infliximab (6) · vedolizumab (6) · etrolizumab (5) · mirikizumab (4) · tofacitinib (4) · etrasimod (3) · golimumab (3) · ozanimod (3) · tetomilast (3) · ABX464 (2) · Adrenal Cortex Hormones (2) · Blood Specimen Collection (2)
Bausch Health Americas, Inc. (13) · Ferring Pharmaceuticals (7) · Shire (7) · AbbVie (6) · Takeda (6) · Hoffmann-La Roche (5) · Pfizer (5) · Warner Chilcott (5) · Dr. Falk Pharma GmbH (4) · Eli Lilly and Company (4) · Janssen Research & Development, LLC (4) · AbbVie (prior sponsor, Abbott) (3) · Celgene (3) · Centocor, Inc. (3) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3)
United States (77) · Canada (52) · Poland (51) · Germany (46) · Belgium (45) · Hungary (44) · Czechia (42) · United Kingdom (42) · Israel (39) · Italy (36) · Japan (35) · Ukraine (35) · Australia (34) · France (34) · Russia (33)
Arena CT.gov Administrator (2) · Bruce Eric Sands (2) · Bruce Sands, MD, PhD (2) · Lindsey Mathew (2)
PMID 32445184, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32766762, PMID 32816215, PMID 32870265, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38425446, PMID 26563167, PMID 28467869, PMID 29028981, PMID 29380251, PMID 29743836, PMID 33127596, PMID 33513294, PMID 34035832, PMID 34165201, PMID 35380664, PMID 35380740, PMID 35934286, PMID 36271912, PMID 36506749, PMID 38778549, PMID 42248437, PMID 16339095, PMID 17324131, PMID 17476675, PMID 19596014, PMID 21255059, PMID 21385195, PMID 22617015, PMID 24067881, PMID 25173754, PMID 25644096, PMID 26861051, PMID 26893500, PMID 27416045
2015 (8), 2004 (5), 2016 (5), 2017 (5), 2008 (2), 2018 (2), 2019 (2), 2023 (2), 2014 (1), R01HD099344 (1)